Markets:

Overview

News

Currencies

International

Treasuries

CorMedix Inc. - Common Stock (NQ:CRMD)

7.630 +0.120 (+1.60%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CorMedix Inc. - Common Stock

Cormedix's Return On Capital Employed Overview ↗

March 31, 2023

Via Benzinga

A Preview Of Cormedix's Earnings ↗

March 29, 2023

Via Benzinga

Cormedix's Return On Capital Employed Insights ↗

December 20, 2022

Via Benzinga

CorMedix Inc Common Stock (CRMD) Q3 2022 Earnings Call Transcript ↗

November 10, 2022

CRMD earnings call for the period ending September 30, 2022.

Via The Motley Fool

CorMedix Inc. (NASDAQ:CRMD) Shareholder Alert: Investigation over Potential Wrongdoing ↗

November 04, 2022

San Diego, CA -- (SBWIRE) -- 11/04/2022 -- Certain directors of CorMedix Inc. are under investigation over potential breaches of fiduciary duties.

Via SBWire

CorMedix Inc. (NASDAQ:CRMD) Shareholder Notice: Update in Lawsuit Announced ↗

September 21, 2022

San Diego, CA -- (SBWIRE) -- 09/21/2022 -- An update was announced in the lawsuit that is pending for certain investors in shares of CorMedix Inc. (NASDAQ:CRMD).

Via SBWire

Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know ↗

August 31, 2022

After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.

Via Benzinga

Recap: Cormedix Q2 Earnings ↗

August 11, 2022

Cormedix (NASDAQ:CRMD) reported its Q2 earnings results on Thursday, August 11, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

CorMedix Slapped With Second FDA Rejection For DefenCath ↗

August 09, 2022

Via Benzinga

If You Invested $1000 In This Stock 10 Years Ago, You Would Have $4,100 Today ↗

August 16, 2022

Cormedix (NASDAQ:CRMD) has outperformed the market over the past 10 years by 2.86% on an annualized basis producing an average annual return of 14.54%. Currently, Cormedix has a market capitalization...

Via Benzinga

Dow Drops Over 100 Points; Verona Pharma Shares Jump ↗

August 09, 2022

U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 100 points on Tuesday.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

August 09, 2022

Via Benzinga

Nasdaq Tumbles 1.5%; BBQ Holdings Shares Spike Higher ↗

August 09, 2022

U.S. stocks traded lower midway through trading, with the Nasdaq dropping around 1.5% on Tuesday.

Via Benzinga

Why U.S. Stocks Are Trading Mixed; Labor Costs Increase Higher-Than-Expected In Q2 ↗

August 09, 2022

U.S. stocks traded mixed this morning, with the Nasdaq dropping around 90 points on Tuesday.

Via Benzinga

Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday ↗

August 10, 2022

Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method.

Via Benzinga

Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday's Mid-Day Session ↗

August 09, 2022

Gainers Verona Pharma plc (NASDAQ: VRNA) shares jumped 83.6% to $12.70 after the company announced ensifentrine met its primary endpoint and secondary endpoints in the Phase 3 ENHANCE-2 trial for COPD....

Via Benzinga

Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful ↗

August 09, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

August 09, 2022

Via Benzinga

Karuna Therapeutics To $276? Plus SVB Leerink Almost Doubles Price Target On This Stock ↗

August 09, 2022

Mizuho boosted the price target for Karuna Therapeutics, Inc. (NASDAQ: KRTX) from $190 to $276. Karuna Therapeutics shares fell 1.3% to $238.00 in pre-market trading.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

August 09, 2022

We're starting off Tuesday with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on today!

Via InvestorPlace

Why Is BIMI International Medical Higher By Around 70%: Here Are 38 Stocks Moving Premarket ↗

August 09, 2022

Gainers BIMI International Medical Inc. (NASDAQ: BIMI) shares rose 69.6% to $1.04 in pre-market trading after Fnu Oudom reported a stake of 44% in the company in 13D.

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

August 08, 2022

Via Benzinga

Biotech Investors: August's Key PDUFA Catalysts You Must Know ↗

July 31, 2022

Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

July 20, 2022

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

June 15, 2022

Via Benzinga

41 Stocks Moving In Monday's Mid-Day Session ↗

May 16, 2022

Gainers Data Storage Corporation (NASDAQ: DTST) shares jumped 51.1% to $3.4750 after the company reported better-than-expected Q1 financial results.

Via Benzinga

73 Biggest Movers From Yesterday ↗

May 17, 2022

Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) shares jumped 65.9% to close at $2.77 on Monday after gaining around 10% on Friday.

Via Benzinga

Cormedix: Q1 Earnings Insights ↗

May 12, 2022

Cormedix (NASDAQ:CRMD) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Cormedix beat estimated earnings by...

Via Benzinga

Cormedix's Return On Capital Employed Insights ↗

March 30, 2022

According to data from Benzinga Pro, during Q4, Cormedix's (NASDAQ:CRMD) reported sales totaled $56.40 thousand. Despite a 9.08% increase in earnings, the company posted a loss of $7.79 million.

Via Benzinga

The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia ↗

March 29, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

CorMedix Inc. - Common Stock (NQ:CRMD)

All News about CorMedix Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today